 "N Govindarajan steps down as Aurobindo Pharma managing director")
N Govindarajan, the managing director of Aurobindo Pharma, has submitted his resignation, the pharmaceutical firm said on October 1.
Govindarajan has decided to step down due to "personal reasons", Aurobindo Pharma said in a regulatory filing. The board of directors has accepted the resignation. It will come into effect from December 31.
Meanwhile, Aurobindo's board has taken note of the appointment of S Damodharan as chief operating officer (COO) for the API vertical. Also, P Yugandhar has been appointed as the chief executive officer (CEO) of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the company focused on generic injectables and oncology business.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%